Glycogen storage disease type 1 (GSD-1) is caused by a deficiency in the activity of glucose-6-phosphatase (G6Pase), an endoplasmic reticulum (ER) associated enzyme. The disease presents with both clinical and biochemical heterogeneity consistent with the existence of two major subgroups, GSD-1a and GSD-1b. GSD-1a, the most prevalent form, is caused by deleterious mutations in the G6Pase gene. We have recently resolved the topology of G6Pase and shown that it contains an odd number of transmembrane helices with the N-terminus localized in the ER lumen and the C-terminus in the cytoplasm. This supports a nine-transmembrane helical model with the enzyme's active site facing the lumen. The topology of G6Pase was further explored by characterizing the three potential Asn-linked glycosylation sites (N96TS, N203AS, and N276SS) in G6Pase. We showed that N96, predicted by the nine-transmembrane model to be located in a 37-residue luminal loop and would be a potential acceptor for oligosaccharides, was the only site that is glycosylated, further supporting the nine transmembrane domain model.It has been proposed that GSD-1b is caused by a deficiency in microsomal glucose-6-phosphate (G6P) transport. By linkage analysis, we have mapped the GSD-1b locus to chromosome 11q23 and a cDNA encoding a microsomal transmembrane protein has been identified. We showed that this cDNA mapped to chromosome 11q23, thus it is a strong candidate for GSD-1b. The crystal structure of the E. coli methionine adenosyltransferase (MAT) has been solved, demonstrating that the active site of the enzyme is at the interface between two identical subunits. To investigate the catalysis of human hepatic MAT, we constructed a series of mutations of the amino acids proposed to be in the active site and one of the putative ATP binding sites. Each of these mutations reduced enzymatic activity significantly, suggesting that the human and E. coli enzyme are arrayed in a similar fashion. We have combined mutational with three dimensional analyses to propose a model for the active site of human MAT.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Intramural Research (Z01)
Project #
1Z01HD000912-19
Application #
6108038
Study Section
Special Emphasis Panel (HDB)
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Cho, Jun-Ho; Kim, Goo-Young; Mansfield, Brian C et al. (2018) Hepatic glucose-6-phosphatase-? deficiency leads to metabolic reprogramming in glycogen storage disease type Ia. Biochem Biophys Res Commun 498:925-931
Cheung, Yuk Yin; Kim, So Youn; Yiu, Wai Han et al. (2007) Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-beta. J Clin Invest 117:784-93
Chou, Janice Y; Mansfield, Brian C (2007) Gene therapy for type I glycogen storage diseases. Curr Gene Ther 7:79-88
Kim, So Youn; Chen, Li-Yuan; Yiu, Wai Han et al. (2007) Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Lett 581:3833-8
Walker, Elizabeth A; Ahmed, Adeeba; Lavery, Gareth G et al. (2007) 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. J Biol Chem 282:27030-6
Yiu, W H; Pan, C-J; Allamarvdasht, M et al. (2007) Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther 14:219-26
Ghosh, A; Allamarvdasht, M; Pan, C-J et al. (2006) Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther 13:321-9
Nguyen, Andrew D; Pan, Chi-Jiunn; Weinstein, David A et al. (2006) Increased scavenger receptor class B type I-mediated cellular cholesterol efflux and antioxidant capacity in the sera of glycogen storage disease type Ia patients. Mol Genet Metab 89:233-8
Kim, So Youn; Nguyen, Andrew D; Gao, Ji-Liang et al. (2006) Bone marrow-derived cells require a functional glucose 6-phosphate transporter for normal myeloid functions. J Biol Chem 281:28794-801
Shieh, J-J; Pan, C-J; Mansfield, B C et al. (2005) In islet-specific glucose-6-phosphatase-related protein, the beta cell antigenic sequence that is targeted in diabetes is not responsible for the loss of phosphohydrolase activity. Diabetologia 48:1851-9

Showing the most recent 10 out of 40 publications